Chronic hypoxia down-regulates tight junction protein ZO-2 expression in children with cyanotic congenital heart defect by Jenkins, EL et al.
Chronic hypoxia down-regulates tight junction protein
ZO-2 expression in children with cyanotic congenital
heart defect
Emma L. Jenkins, Massimo Caputo, Gianni D. Angelini and Mohamed T. Ghorbel*
Bristol Heart Institute, School of Clinical Sciences, University of Bristol, Bristol, UK
Abstract
Aims Tight junction protein zonula occludens protein 2 (ZO-2) is a member of the membrane-associated guanylate kinases
protein family known to be expressed at tight junctions of epithelial and endothelial cells and at adherens junctions (AJs) in
cardiomyocytes. Little is known about ZO-2 expression and function in the human heart. Here, we examined the hypothesis
that chronic hypoxia down-regulates ZO-2 expression in human myocardium and cultured rat cardiomyocytes.
Methods and results Patients with a diagnosis of cyanotic (n = 10) or acyanotic (n = 10) Tetralogy of Fallot undergoing sur-
gical repair were used to examine ZO-2 messenger RNA and protein expression by real time-PCR, immunohistochemistry,
and western blotting. A model of cultured rat cardiomyocytes was used to measure ZO-2 and AJ proteins levels in response
to hypoxia and to investigate ZO-2 cellular localization. We showed that ZO-2 is expressed in myocardial tissue in acyanotic
and cyanotic children with congenital heart defects. ZO-2 was speciﬁcally down-regulated in cyanotic myocardium at both
the messenger RNA and protein levels when compared with acyanotic patients. This speciﬁc down-regulation can be mimicked
in cultured rat cardiomyocytes by treating them with hypoxic conditions conﬁrming that ZO-2 gene down-regulation is specif-
ically due to cyanosis. Furthermore, in addition to its cytoplasmic expression, ZO-2 showed nuclear expression in cultured rat
cardiomyocytes suggesting potential role in transcription regulation.
Conclusions Hypoxia down-regulates ZO-2 expression in both cyanotic patient’s myocardium and cultured rat
cardiomyocytes. This down-regulation suggest an involvement of ZO-2 in cardiac remodelling of AJs in cyanotic children
and may explain the greater susceptibility of cyanotic patients to corrective heart surgery.
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Introduction
Congenital heart defects (CHDs) account for the largest number
of birth defects in humans, with an incidence of ~8 per 1000 live
births (British Heart Foundation data 2004), and can lead to
heart failure. Tetralogy of Fallot (TOF) is a common form of cya-
notic CHD, with an incidence rate of 1 out of 2000 newborns.
Currently, primary correction at a young age is the treatment
of choice. However, corrective surgery could result in an
ischaemia/reperfusion injury.
Cyanotic paediatric patients undergoing cardiac surgery
are exposed to a chronic hypoxic state that can reduce their
antioxidant reserve capacity, leading to a greater susceptibil-
ity to the oxidative stress of ischaemia and reperfusion at the
time of surgical correction.1–3 Although corrective surgery of
heart defects is successful, there is an increased risk of mor-
bidity and mortality in cyanotic children compared with
acyanotic.4 We recently examined the effect of chronic
hypoxia on the transcriptomic proﬁle in patients with TOF
using gene microarray.5 Out of the differentially expressed
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genes, zonula occludens protein 2 (ZO-2) transcript level
showed a signiﬁcant decrease in cyanotic patients compared
with acyanotic. ZO proteins (ZO-1, ZO-2, and ZO-3) belong to
the membrane associated guanylate kinase (MAGUK)-like
protein family characterized by containing PDZ [post synaptic
density protein (PSD95), Drosophila disc large tumor suppres-
sor (Dlg1), and zonula occludens-1 protein (zo-1)], Src homol-
ogy 3, and guanylate kinase domains. ZO-2, also named tight
junction protein 2, is expressed at tight junctions (TJs) of
epithelial and endothelial cells, which are membrane
structures that regulate the passage of ions and molecules
through the paracellular pathway. ZO-2 is a structural protein,
which links transmembrane TJ proteins to the actin cytoskel-
eton and was ﬁrst identiﬁed as a 160 kDa protein, which
co-immunoprecipitates with ZO-1.6 ZO proteins dimerize at
the TJ and form ZO-1/ZO-2 and ZO-1/ZO3 complexes.7
ZO-1/ZO-2 are highly homologous proteins but differ at the
C terminal where ZO-2 contains an alternatively spliced
region containing a β-motif. Both proteins have been shown
to bind with other TJ expressed proteins: occludin and
α-catenin in vitro.8 ZO proteins have unique motifs not com-
mon in other MAGUK proteins, nuclear localization signals,9
and nuclear export signals.10 Additionally, recent data indi-
cate that ZO-2 nuclear or cell surface localization is strongly
dependent on the state of cell–cell contact.9
Furthermore, increased nuclear staining has been observed
when epithelial cells were subjected to environmental stress such
as heat shock or chemical insult.11 Nuclear ZO-2 has been shown
to bind to a number of signalling molecules including FBJ murine
osteosarcoma viral oncogene homolog (FOS), jun proto-
oncogene (JUN), and CCAAT/enhancer binding protein (C/EBP).12
Data from ZO-2 down-regulation studies show it has
signiﬁcant structural importance in the cell. Small interfering
RNA silencing of ZO-2 alters the gate function of TJs, the
fencing properties, and actin distribution at the membrane
of epithelial cells.13 ZO-2 knock-out mice die during devel-
opment showing that ZO-2 is critical for mammalian
development.14
Very little is known about human ZO expression. Northern
blotting experiments performed on adult human epithelial
tissue showed ZO-2 gene isoforms A and C are tissue speciﬁc,
and both are expressed in the adult human heart.15 A later
study showed ZO-1 is implicated in end stage human failing
hearts.16 ZO-1 down-regulation was observed at intercalated
discs, which coincided with reduced levels of Cx43, a gap junc-
tion protein.16 The present study is the ﬁrst to show ZO-2 ex-
pression and deregulation in cyanotic and acyanotic children’s
myocardium at both the gene and protein level. We speciﬁ-
cally show a down-regulation of ZO-2 messenger RNA (mRNA)
and protein expression in patients undergoing corrective
surgery for cyanotic heart defects compared with acyanotic
patients. The expression of other AJ proteins was not affected
by ZO-2 down-regulation. This can be mimicked experimen-
tally by treating postnatal rat cardiomyocytes with hypoxic
conditions. These data suggest that ZO-2 down-regulation
contributes to cardiac remodelling of AJs in cyanotic children
but not in acyanotic patients, which coincides with cyanotic
children being more susceptible to reoxygenation injury post
corrective surgery when compared with acyanotic children.
Methods
Antibodies
All antibodies used in this study are as follows: anti-ZO-1 (Zymed
33-9100), anti-ZO-2 (Lifespan Biosciences LS-C26439), anti-
N-cadherin (BD Transduction Laboratories 610920), anti-β-catenin
(Sigma C2206), anti α-catenin (Zymed 13-9700), anti-β-actin
(Sigma A5441), and anti-glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) (Cell Signalling 14C10).
Children myocardium biopsies
The collection of human right ventricle specimens used in this
study was approved by the North Somerset and South Bristol
Research Ethics Committee (REC reference 07/H0106/172),
The National Research Ethics Service, England. Parental
informed written consent was gained for all patients. Patients
with a diagnosis of cyanotic or acyanotic TOF undergoing surgi-
cal repair at the Bristol Royal Hospital for Children were studied.
Twenty patients with a diagnosis of cyanotic (n=10) or acyanotic
(n=10) TOF undergoing surgical repair at the Bristol Royal
Hospital for Children were studied. All patients were in stable
condition without preoperative respiratory or inotropic support.
Patients with cyanotic TOF presented with several episodes of
spells and repeated saturation measurements of less than 90%
(mean, 78.9 ± 6.6%), whereas patients with acyanotic TOF did
not have a history of cyanotic spells and presented with
saturations of greater than 90% (mean, 94.7 ± 2.2%).
Myocardium biopsies were collected from 10 acyanotic
and 10 cyanotic children immediately after institution of car-
diopulmonary bypass (CPB). This collection time-point during
the CPB excludes the different CPB-related acute ischemic
myocardial injury effect in these two groups. Biopsies for pro-
tein extraction were collected in Eppendorfs and snap frozen
in liquid nitrogen and stored long term at 80°C. Once
thawed tissue was homogenized and lysed in lysis buffer [Tris
10mM pH7.5, EDTA 10mM, NaCl 150mM, triton X100 1%,
SDS 0.1% and 1% proteases inhibitor cocktail (Roche
04693116001)] and centrifuged at 1400 rpm for 15min
(n = 5 for both acyanotic and cyanotic). Samples for RNA
isolation were collected in ribonuclease free Eppendorfs
containing RNAlater solution™ (Qiagen 76104) and stored at
4°C until RNA extraction performed (n = 4 for both acyanotic
and cyanotic).
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Rat cardiomyocyte cell culture and treatment
All the procedures involving laboratory animals conformed to
the guidelines and regulations of the University of Bristol and
the United Kingdom Home Ofﬁce. Cardiomyocytes were pre-
pared from neonatal (P1–2) Wistar rat myocardium cells as
described previously.17 Cells were grown in vitro for 3 days,
then treated with hypoxia for 24 h by incubating in a hypoxic
chamber containing 5% CO2 and 0.2% O2 at 37°C. Untreated
cells used as a control were cultured in a humidiﬁed incuba-
tor with 5% CO2 at 37°C.
RT and real time PCR
Ribonucleic acid was isolated from human myocardium sam-
ples using RNeasy Micro Kit (Qiagen 74004) and reverse
transcribed using Retroscript® kit (Ambion AM1710). Two
microlitre total complementary DNA (cDNA) was used in the
real-time-PCR reaction, which contained the following: 2x
SYBR® green (ABgene), Quantitect Primer assay speciﬁc for
ZO-2 (133bp) or 18 s (103bp) (Qiagen QT00010290 and
QT00199374, respectively). Total solutions were loaded into
capillaries and run for 50 cycles at an annealing temperature
of 50°C in a Lightcycler 3 (Roche). Each sample was run in
duplicate, and ZO-2 levels were normalized to 18 s. PCR end
products were run on a 1% agarose gel to conﬁrm an ampliﬁed
DNA fragment of the correct size.
Western blotting
Protein samples were prepared by adding 4x Laemmli buffer
(0.24M Tris pH6.8, 6% SDS, 40% sucrose, 0.04% bromophenol
blue and 10% β-mercaptoethanol), heating to 95°C for 5min
and were loaded on a 8–10% SDS gel. Separated proteins were
transferred to Hybond™ nitrocellulose membrane (Amersham
RPN303D), which were subsequently blocked in 5% non-fat
dry milk/TBS-T (TBS-T; 20mM Tris pH7.4, 1.37M NaCl, 1%
Tween) for 1h and incubated in primary antibodies overnight
at 4°C. Membranes were washed three times in TBS-T then
incubated in appropriate anti-rabbit or anti-mouse secondary
antibody (Amersham NA934 and NA931, respectively) for 1h
at RT. Membranes were washed three times in TBS-T, and anti-
body bound horseradish peroxidase (HRP) was detected using
ECL (Amersham RPN2132 or RPN2134); membranes were
exposed to HyperﬁlmTM (Amersham # 28906837). Protein bands
were quantiﬁed using NIH Image J software.
Immunohistochemistry
Right ventricular specimens were ﬁxed in 4% paraformaldehyde,
washed in phosphate-buffered saline (PBS), embedded in
parafﬁn, and 4μm sections were obtained. Immunohistochem-
istry was performed using the ABC-Kit from Dakocytomation.
Slides were observed with an Olympus B40 microscope. Pictures
were taken using a Media Cybernetics camera (Bethesda, MD,
USA) and pro-image plus software (Bethesda).
Immunocytochemistry
Rat cardiomyocytes grown on coverslips were ﬁxed for 15min
in 3% PFA and washed three times in PBS. Coverslips were
incubated in NH4Cl for 10min and blocked in 10% HS for
20min. Coverslips were then incubated in primary antibodies
overnight at 4°C and the following day washed three times
in PBS and incubated in secondary antibodies: CY2 and CY3
(Jackson Labs) for 1 h at RT. After washing three times in
PBS, slides were mounted with Vectorshield Mounting
medium containing DAPI (# H-1200 Vector Laboratories).
Fluorescent cell imaging was achieved using a Zeiss LSM 510Meta
confocal microscope (Carl Zeiss Ltd, Cambridge, UK).
Statistical analysis
All data were analysed using the software Instat 3.1
(GraphPad). Results are expressed as ± Standard Error of Mean
(±SEM). The normality of the population was assumed. Statis-
tical signiﬁcance was assessed by Student’s t-test. A value of
P< 0.05 was considered to be statistically signiﬁcant.
Results
Clinical data are summarized in Table 1. The two groups were
comparable in terms of age. None of the patients recruited in
this study had a previous palliative surgery. There were no
deaths and no major morbidity in both groups. CPB time
was longer in the cyanotic group, who required more exten-
sive trans-annular patching and reconstruction of the pulmo-
nary artery compared with the acyanotic patients.
Table 1 Baseline patients’ characteristics and clinical
outcomes
Cyanotic
(n=10)
Acyanotic
(n=10) P-value
Age (months) 5.7± 2.1 6.0±1.8 0.73
Pre-operative O2
saturations (%)
78.9± 6.6 94.7±2.2 0.001
Cross-clamp time (min) 75.1± 11.3 54.4±11.8 0.001
CPB time (min) 127.3± 18.4 88.1±13.4 0.001
In-hospital mortality 0 0 —
Previous surgery 0 0 —
Use of preoperative
β-blockers
5 1 —
Data are mean± standard deviation.
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ZO-2 protein is expressed in human heart sections of
both cyanotic and acyanotic congenital heart patients
Immunohistochemical analysis of ﬁxed paediatric heart
biopsy sections showed expression of ZO-2 in heart tissue
taken from both acyanotic and cyanotic patients undergoing
corrective surgery for CHD (Figure 1).
ZO-2 mRNA expression is down-regulated in cyanotic
myocardium compared with acyanotic patients
Total RNAs were extracted from the biopsies and reverse
transcribed to produce cDNA. Realtime-PCR analysis of
human cDNA samples using ZO-2 speciﬁc primers showed a
signiﬁcant down-regulation of ZO-2 mRNA expression in
cyanotic (n = 4) compared with acyanotic patients (Figure 2).
ZO-2 protein expression is down-regulated in cyanotic
patients compared with acyanotic
Western blot analysis of protein extracted from children’s
myocardium biopsies reveals a speciﬁc down-regulation of
ZO-2 protein expression in cyanotic patients (n = 5), coincid-
ing with the down-regulation of ZO-2 at the mRNA level. To
see if this was a speciﬁc down-regulation of the ZO-2 protein
or a result of altered expression of all AJ expressed proteins,
we also probed for a number of AJ expressed proteins: ZO-1,
N-cadherin α-catenin and β-catenin. The levels of all other AJ
expressed proteins were not signiﬁcantly affected (Figure 3).
Figure 1 Expression of zonula occludens protein 2 (ZO-2) in acyanotic and cyanotic paediatric myocardium tissue. Immunohistochemical analysis of
parafﬁn embedded heart tissue from an acyanotic and cyanotic patient using ZO-2 speciﬁc antibody. 3,3’-Diaminobenzidine (DAB) staining reveals
expression of ZO-2 in both tissues when compared with controls, with a visible decrease in expression in cyanotic tissue compared with acyanotic.
Magniﬁcation: x200.
Figure 2 Down-regulation of zonula occludens protein 2 (ZO-2) messen-
ger RNA (mRNA) expression in cyanotic compared with acyanotic
patients. Total RNA isolated from myocardium biopsies, reverse
transcribed, and PCR performed on complementary DNA using primers
for ZO-2 and 18 s. A. PCR products run on agarose gel [lanes 1–4
acyanotic samples (AC), lanes 5–8 cyanotic samples (CC)]. B. Ratio of AC
mRNA copy number (arbitrary units) compared with CC showing a
down-regulation of ZO-2 in CC children compared with AC, all values nor-
malized to 18 s mRNA levels. Data are mean ± SEM ** = P< 0.01 (n = 4).
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Hypoxic conditions produce a down-regulation of
ZO-2 in cultured rat cardiomyocytes
An in vitro model of cyanosis would be advantageous as human
biopsies are not widely available. To mimic the low-oxygen con-
ditions seen in cyanotic children, isolated rat cardiomyocytes
grown in culture were subjected to 24h hypoxia in a hypoxic
chamber. After 24h, cells were lysed and western blotting
performed. A signiﬁcant down-regulation of ZO-2 protein
expression was observed compared with control cells, which
were cultured in a humidiﬁed incubator with 5% CO2 at 37°C
(Figure 4). As with children’s samples, no other components of
AJs junctions (ZO-1, actin, β-catenin, α-catenin, and N-cadherin)
Figure 3 Down-regulation of zonula occludens protein 2 (ZO-2) protein expression in myocardium of cyanotic compared with acyanotic patients.
Myocardium biopsies were lysed to isolate protein content and western blot analysis performed probing for ZO-2, ZO-1, N-cadherin, β-catenin,
and GAPDH. ZO-2 protein expression was signiﬁcantly down-regulated in cyanotic biopsies compared with acyanotic, whereas no difference in
any other adherens junction expressed proteins was detected. All results were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
levels. Data are mean ± SEM * = P< 0.05 (n = 5).
Figure 4 Down-regulation of zonula occludens protein 2 (ZO-2) levels in rat cardiomyocytes following 24 h hypoxic treatment. Cells were treated with
hypoxic conditions by incubating in a chamber with 5% CO2/ 0.2% O2. After 24 h, cells were lysed, and western blot analysis performed probing for
ZO-2, ZO-1, N-cadherin, β-catenin, and β-actin, normalizing all results to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) levels. ZO-2 protein
expression was signiﬁcantly down-regulated in hypoxic treated cells compared with untreated cells (control), whereas no difference in ZO-1,
N-cadherin, β-catenin, or β-actin levels was detected between treated and untreated cells. Data are mean ± SEM ** = P< 0.01 (n = 4).
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were signiﬁcantly affected following hypoxia, showing that ZO-2
down-regulation is independent of other AJ proteins.
ZO-2 shows a cytoplasmic and nuclear localization in
neonatal heart cardiomyocytes
Immunocytochemistry analysis of neonatal rat cardiomyocytes
showed mainly cytoplasmic and nuclear expression of ZO-2
(Figure 5). In addition, some ZO-2 expression is also observed
close to AJ (Figure 5).
Discussion
In this study, we report ZO-2 protein expression in human
paediatric heart myocardium tissue. ZO-2 has been shown
to be expressed at AJs in the adult rat heart.8 However, to
our knowledge, no other previous study has shown expres-
sion of ZO-2 protein in the human paediatric congenital
heart. ZO-2 is expressed in the myocardium of both cyanotic
and acyanotic children. Here, we show that ZO-2 mRNA
expression level is down-regulated in cyanotic myocardium
compared with acyanotic patients. This result conﬁrmed our
previous ﬁndings by microarray analysis.5
Our western blotting data reveal a speciﬁc down-regulation
of ZO-2 protein expression in cyanotic patients, correlating with
the down-regulation of ZO-2 mRNA level. All the other AJ
proteins examined showed no alteration by chronic hypoxia.
In an in vitro cell model mimicking cyanosis, chronic hyp-
oxia produced a down-regulation of ZO-2 protein in a similar
way to that obtained in the human biopsies. This model
would allow future functional studies into the mechanisms
underlying ZO-2 down-regulation by hypoxia to be performed
and to investigate means to restore ZO-2 expression to nor-
mal levels. Incubating cardiomycytes for 24 h in a hypoxic
chamber used in this study is a widely used protocol to
induce hypoxia in rat cardiomyocytes.17
A down-regulation of ZO-1 following hypoxia has been
shown to affect cell membrane junction structures of other
organs.18 In the murine brain, TJ organization is disrupted,
following hypoxia, causing an increase in permeability in the
blood brain barrier.18 Additionally, it has been shown, in
mouse, that ischemia/reperfusion injury decrease the expres-
sion of ZO-2 in the cytoskeleton, and ischemic precondition-
ing preserves the integrity of tight junction structure and
function in coronary endothelial cells.19 Our study suggests
that ZO-2 is a potential protein implicated in cardiac remod-
elling in children with cyanotic heart defects that could
contribute to long-term myocardial dysfunction and heart
failure in cyanotic patients compared with acyanotic. AJ dis-
ruption in myocardium of cyanotic children may contribute
to reoxygenation injury in cyanotic patients following CPB
used during surgery. AJ disruption is seen in cardiomyocytes
and endothelial cells following CPB in pigs.20
Figure 5 Localization of zonula occludens protein 2 (ZO-2) in cultured
rat cardiomyocytes. Cells were cultured for 5 days in vitro then ﬁxed
and stained with speciﬁc antibodies. Cardiomyocytes were stained for
ZO-2 (green) and N-cadherin (red) then counterstained for nuclei with
4’,6-diamidino-2-phenylindole (DAPI) (blue). ZO-2 shows cytoplasmic
and nuclear expression. N-cadherin shows adherens junction expres-
sion. Bar = 20 μm.
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The nuclear localization of ZO-2 and interaction with
transcription factors12 provide evidence for a dual role for
the protein; as a structural organizer at the plasma mem-
brane linking TJs to the cytoskeleton and an involvement in
transcriptional regulation and regulating gene expression.
In conclusion, hypoxia down-regulates ZO-2 expression in
both cyanotic patients’ myocardium and cultured rat
cardiomyocytes. This down-regulation evokes an involvement
of ZO-2 in cardiac remodelling of AJs in cyanotic children and
may explain the greater susceptibility of cyanotic patients to
myocardial reoxygenation injury seen during corrective heart
surgery.
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